Hantz Financial Services Inc. Cuts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hantz Financial Services Inc. cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.1% during the 4th quarter, Holdings Channel reports. The firm owned 138,910 shares of the biopharmaceutical company’s stock after selling 22,862 shares during the quarter. Hantz Financial Services Inc.’s holdings in Halozyme Therapeutics were worth $6,641,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in HALO. Verdence Capital Advisors LLC grew its stake in Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 252 shares in the last quarter. GAMMA Investing LLC grew its stake in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares in the last quarter. Juncture Wealth Strategies LLC grew its stake in Halozyme Therapeutics by 3.6% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after buying an additional 415 shares in the last quarter. Diversify Advisory Services LLC boosted its stake in shares of Halozyme Therapeutics by 8.5% in the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 418 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 7.7% in the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company’s stock valued at $407,000 after purchasing an additional 507 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on HALO shares. JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $60.89.

Halozyme Therapeutics Trading Down 0.3 %

Shares of NASDAQ HALO opened at $55.83 on Thursday. The stock has a market cap of $7.10 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The firm has a 50-day moving average of $50.28 and a 200 day moving average of $54.28.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.